| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA850: Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy |
|
Medicine details |
|
| Medicine name | amivantamab (Rybrevant®) |
| Formulation | 50 mg/ml concentrate for solution for infusion |
| Reference number | 4612 |
| Indication | Monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/12/2021 |
| NICE guidance | |